Active substance
Levothyroxine
- SFDA 16
- US FDA 35
- Health Canada 34
- US price lines 59
- NHS prices 10
- WHO EML 1
- Safety 12
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ELTROXIN 0.05MG TAB | 0.05 mg | Tablet · Oral use | 100 Tablet Container | SAR 20.00 | NCE · Prescription | ASPEN PHARMA TRADING LIMITED (APTL) | Valid |
| ELTROXIN 0.1MG TAB | 0.1 mg | Tablet · Oral use | 100 Tablet Container | SAR 22.35 | NCE · Prescription | ASPEN PHARMA TRADING LIMITED (APTL) | Valid |
| EUTHYROX | 0.05 mg | Tablet · Oral use | 100 Tablet Container | SAR 22.25 | NCE · Prescription | Merck Healthcare KGaA | Valid |
| EUTHYROX | 0.025 mg | Tablet · Oral use | 100 Tablet Container | SAR 17.05 | NCE · Prescription | Merck Healthcare KGaA | Valid |
| EUTHYROX | 0.15 mg | Tablet · Oral use | 100 Tablet Container | SAR 36.55 | NCE · Prescription | Merck Healthcare KGaA | Valid |
| EUTHYROX | 0.1 mg | Tablet · Oral use | 100 Tablet Container | SAR 31.35 | NCE · Prescription | Merck Healthcare KGaA | Valid |
| Levogand | 50 µg | Tablet · Oral use | 100 Bottle | SAR 20.00 | Generic · Prescription | ADEL AHMED AL-SHAEIR PHARMACEUTICAL COMPANY | Valid |
| Levogand | 25 µg | Tablet · Oral use | 100 Bottle | SAR 15.35 | Generic · Prescription | ADEL AHMED AL-SHAEIR PHARMACEUTICAL COMPANY | Valid |
| Levogand | 100 µg | Tablet · Oral use | 100 Bottle | SAR 22.35 | Generic · Prescription | ADEL AHMED AL-SHAEIR PHARMACEUTICAL COMPANY | Valid |
| ELTROXIN 0.05MG TAB | 0.05 mg | Tablet · Oral use | 100 Tablet Container | SAR 20.00 | NCE · Prescription | GLAXO SAUDI ARABIA | Withdrawn by MAH · Not Marketed |
| ELTROXIN 0.05MG TAB | 0.05 mg | Tablet · Oral use | 100 Tablet Container | SAR 20.00 | NCE · Prescription | ASPEN | Withdrawn by MAH · Not Marketed |
| ELTROXIN 0.1MG TAB | 0.1 mg | Tablet · Oral use | 100 Tablet Container | SAR 29.15 | NCE · Prescription | GLAXO SAUDI ARABIA | Withdrawn by MAH · Not Marketed |
| ELTROXIN 0.1MG TAB | 0.1 mg | Tablet · Oral use | 100 Tablet Container | SAR 29.15 | NCE · Prescription | ASPEN | Withdrawn by MAH · Not Marketed |
| L- THYROX HEXAL 100MCG TABLETS | 0.1 mg | Tablet · Oral use | 50 Tablet Container | SAR 15.55 | Generic · Prescription | HEXAL | Withdrawn by MAH · Not Marketed |
| L- THYROX HEXAL 150MCG TABLETS | 150 µg | Tablet · Oral use | 50 Tablet Container | SAR 18.05 | Generic · Prescription | HEXAL | Withdrawn by MAH · Not Marketed |
| L- THYROX HEXAL 50MCG TABLETS | 0.05 mg | Tablet · Oral use | 50 Tablet Container | SAR 9.50 | Generic · Prescription | HEXAL | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE BIPOLAR I DEPRESSION; HYPOTHYRODISM; THYROID CANCER-PAPILLARY, FOLLICULAR, HURTHLE CELL CARCINOMA-SUPPORTIVE CARE
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| UNITHROID | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet · oral | STEVENS J | Prescription | 21 Aug 2000 |
| LEVOXYL | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet · oral | KING PHARMS | Prescription | 25 May 2001 |
| LEVO-T | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet · oral | CEDIPROF INC | Prescription | 1 Mar 2002 |
| LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet · oral | MYLAN | Prescription | 5 Jun 2002 |
| SYNTHROID | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet · oral | ABBVIE | Prescription | 24 Jul 2002 |
| THYRO-TABS | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet · oral | ALVOGEN | Prescription | 24 Oct 2002 |
| LEVOLET | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet · oral | GENUS LIFESCIENCES | Prescription | 6 Jun 2003 |
| TIROSINT | 0.025MG; 0.05MG; 0.075MG; 0.1MG; 0.125MG; 0.15MG; 0.112MG; 0.137MG; 0.088MG; 0.175MG; 0.2MG; 0.013MG; 0.0375MG; 0.044MG; 0.0625MG | capsule · oral | IBSA | Prescription | 13 Oct 2006 |
| LEVOTHYROXINE SODIUM | 100MCG/VIAL; 200MCG/VIAL; 500MCG/VIAL | powder · intravenous | FRESENIUS KABI USA | Prescription | 24 Jun 2011 |
| TIROSINT-SOL | 13MCG/ML; 25MCG/ML; 50MCG/ML; 75MCG/ML; 88MCG/ML; 100MCG/ML; 112MCG/ML; 125MCG/ML; 137MCG/ML; 150MCG/ML; 175MCG/ML; 200MCG/ML; 37.5MCG/ML; 44MCG/ML; 62.5MCG/ML | solution · oral | IBSA | Prescription | 15 Dec 2016 |
| LEVOTHYROXINE SODIUM | 100MCG/VIAL; 200MCG/VIAL; 500MCG/VIAL | powder · intravenous | MAIA PHARMS INC | Prescription | 21 Dec 2018 |
| LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet · oral | LUPIN | Prescription | 18 Jan 2019 |
| LEVOTHYROXINE SODIUM | 100MCG/5ML (20MCG/ML); 200MCG/5ML (40MCG/ML); 500MCG/5ML (100MCG/ML) | solution · intravenous | FRESENIUS KABI USA | Prescription | 11 Apr 2019 |
| LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet · oral | ACCORD HLTHCARE | Prescription | 19 Oct 2020 |
| THYQUIDITY | 100MCG/5ML | solution · oral | STEVENS J | Prescription | 30 Nov 2020 |
| LEVOTHYROXINE SODIUM | 100MCG/ML | solution · intravenous | HIKMA | Prescription | 17 May 2021 |
| LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet · oral | WATSON LABS TEVA | Prescription | 10 May 2022 |
| LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet · oral | MACLEODS PHARMS | Prescription | 21 Dec 2022 |
| LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet · oral | ASCENT PHARMS INC | Prescription | 18 Jan 2023 |
| LEVOTHYROXINE SODIUM | 100MCG/VIAL; 200MCG/VIAL; 500MCG/VIAL | powder · intravenous | ZYDUS PHARMS | Prescription | 24 Mar 2023 |
| LEVOTHYROXINE SODIUM | 100MCG/VIAL | powder · intravenous | XIROMED | Prescription | 29 Nov 2024 |
| LEVOTHYROXINE SODIUM | 100MCG/VIAL; 200MCG/VIAL; 500MCG/VIAL | powder · intravenous | ONESOURCE SPECIALTY | Prescription | 5 Mar 2025 |
| LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium; 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet · oral | ALEMBIC | Prescription | 20 May 2026 |
| LEVOXYL | 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | KING PHARMS | Discontinued | 25 May 2001 |
| EUTHYROX | 0.025MG; 0.05MG; 0.075MG; 0.088MG; 0.1MG; 0.112MG; 0.125MG; 0.137MG; 0.15MG; 0.175MG; 0.2MG; 0.3MG | tablet · oral | EMD SERONO INC | Discontinued | 31 May 2002 |
10 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-LEVOTHYROXINE | 02534681 | 100 MCG | TABLET · ORAL | APOTEX INC |
| APO-LEVOTHYROXINE | 02534703 | 300 MCG | TABLET · ORAL | APOTEX INC |
| APO-LEVOTHYROXINE | 02550709 | 25 MCG | TABLET · ORAL | APOTEX INC |
| APO-LEVOTHYROXINE | 02550717 | 50 MCG | TABLET · ORAL | APOTEX INC |
| APO-LEVOTHYROXINE | 02550725 | 75 MCG | TABLET · ORAL | APOTEX INC |
| APO-LEVOTHYROXINE | 02550733 | 88 MCG | TABLET · ORAL | APOTEX INC |
| APO-LEVOTHYROXINE | 02550741 | 112 MCG | TABLET · ORAL | APOTEX INC |
| APO-LEVOTHYROXINE | 02550768 | 125 MCG | TABLET · ORAL | APOTEX INC |
| APO-LEVOTHYROXINE | 02550776 | 137 MCG | TABLET · ORAL | APOTEX INC |
| APO-LEVOTHYROXINE | 02550784 | 150 MCG | TABLET · ORAL | APOTEX INC |
| APO-LEVOTHYROXINE | 02550792 | 175 MCG | TABLET · ORAL | APOTEX INC |
| APO-LEVOTHYROXINE | 02550806 | 200 MCG | TABLET · ORAL | APOTEX INC |
| ELTROXIN | 02213192 | 50 MCG | TABLET · ORAL | ASPEN PHARMACARE CANADA INC. |
| ELTROXIN | 02213206 | 100 MCG | TABLET · ORAL | ASPEN PHARMACARE CANADA INC. |
| ELTROXIN | 02213214 | 150 MCG | TABLET · ORAL | ASPEN PHARMACARE CANADA INC. |
| ELTROXIN | 02213222 | 200 MCG | TABLET · ORAL | ASPEN PHARMACARE CANADA INC. |
| LEVOTHYROXINE SODIUM FOR INJECTION | 02245948 | 500 MCG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | FRESENIUS KABI CANADA LTD |
| LEVOTHYROXINE SODIUM FOR INJECTION | 02461714 | 200 MCG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | AVIR PHARMA INC. |
| LEVOTHYROXINE SODIUM FOR INJECTION | 02461722 | 500 MCG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | AVIR PHARMA INC. |
| LEVOTHYROXINE SODIUM INJECTION | 02499916 | 40 MCG / ML | SOLUTION · INTRAVENOUS; INTRAMUSCULAR | FRESENIUS KABI CANADA LTD |
| LEVOTHYROXINE SODIUM INJECTION | 02499924 | 100 MCG / ML | SOLUTION · INTRAMUSCULAR; INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| SYNTHROID | 02171228 | 112 MCG | TABLET · ORAL | BGP PHARMA ULC |
| SYNTHROID | 02172062 | 25 MCG | TABLET · ORAL | BGP PHARMA ULC |
| SYNTHROID | 02172070 | 50 MCG | TABLET · ORAL | BGP PHARMA ULC |
| SYNTHROID | 02172089 | 75 MCG | TABLET · ORAL | BGP PHARMA ULC |
9 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LEVO-T 100 MCG TABLET | $0.04972 | per EA | 23 Sep 2026 |
| US NADAC | LEVO-T 112 MCG TABLET | $0.05879 | per EA | 23 Sep 2026 |
| US NADAC | LEVO-T 125 MCG TABLET | $0.05704 | per EA | 23 Sep 2026 |
| US NADAC | LEVO-T 137 MCG TABLET | $0.06388 | per EA | 23 Sep 2026 |
| US NADAC | LEVO-T 150 MCG TABLET | $0.05858 | per EA | 23 Sep 2026 |
| US NADAC | LEVO-T 175 MCG TABLET | $0.07347 | per EA | 23 Sep 2026 |
| US NADAC | LEVO-T 200 MCG TABLET | $0.08099 | per EA | 23 Sep 2026 |
| US NADAC | LEVO-T 25 MCG TABLET | $0.03506 | per EA | 23 Sep 2026 |
| US NADAC | LEVO-T 300 MCG TABLET | $0.10428 | per EA | 23 Sep 2026 |
| US NADAC | LEVO-T 50 MCG TABLET | $0.04073 | per EA | 23 Sep 2026 |
| US NADAC | LEVO-T 75 MCG TABLET | $0.04612 | per EA | 23 Sep 2026 |
| US NADAC | LEVO-T 88 MCG TABLET | $0.04947 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Levothyroxine sodium 100microgram tablets | £0.86 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Levothyroxine sodium 100micrograms/5ml oral solution sugar free | £45.61 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Levothyroxine sodium 12.5microgram tablets | £10.87 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Levothyroxine sodium 125micrograms/5ml oral solution sugar free | £185.00 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Levothyroxine sodium 25microgram tablets | £0.87 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Levothyroxine sodium 25micrograms/5ml oral solution sugar free | £23.13 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Levothyroxine sodium 50microgram tablets | £0.86 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Levothyroxine sodium 50micrograms/5ml oral solution sugar free | £21.40 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Levothyroxine sodium 75microgram tablets | £2.02 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Levothyroxine sodium 75micrograms/5ml oral solution sugar free | £163.50 | 100 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 18.7. Thyroid hormones and antithyroid medicines · core
Hypothyroidism
Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt) (EMLc)
Safety signals and safety-related labeling changes
- US FDA 4 May 2026 LEVO-T — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 20 Feb 2024 SYNTHROID — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 16 Nov 2023 THYRO-TABS — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 16 Nov 2023 TIROSINT-SOL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - MHRA 19 May 2021 Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products
If a patient reports persistent symptoms when switching between different levothyroxine tablet formulations, consider consistently prescribing a specific product known to be well tolerated by the patient. If symptoms or poor control of thyroid function persist (despite adhering to a specific product), consider prescribing levothyroxine in an oral solution formulation. - US FDA 10 Dec 2018 UNITHROID — safety-related labeling change
Labeling sections changed: Boxed Warning - US FDA 14 Sep 2018 NOVOTHYROX — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Drug Interactions; Use in Specific Populations - EMA PRAC 12 Jul 2018 PRAC signal: Interaction possibly leading to decreased levothyroxine efficacy and hypothyroidism
Action for MAH: update of the product information: No - EMA PRAC 8 Feb 2018 PRAC signal: Interaction possibly leading to decreased levothyroxine efficacy and hypothyroidism
Action for MAH: update of the product information: Yes - US FDA 8 Dec 2017 TIROSINT — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 30 Nov 2017 PRAC signal: Interaction possibly leading to decreased levothyroxine efficacy and hypothyroidism
Action for MAH: update of the product information: No - EMA PRAC 6 Jul 2017 PRAC signal: Interaction possibly leading to decreased levothyroxine efficacy and hypothyroidism
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.